JEFFS ROGER 4

What Happened Roger Jeffs, a director of Axsome Therapeutics (NASDAQ: AXSM), sold a total of 572 shares in two open‑market transactions. On 2026-06-10 he sold 286 shares at $246.18 for $70,407, and on 2026-06-11 he sold 286 shares at $249.12 for $71,248, for combined proceeds of approximately $141,655. These were sales (dispositions), not purchases.

Key Details

• Transactions: Open‑market sales (S) of 286 shares on 2026-06-10 at $246.18 ($70,407) and 286 shares on 2026-06-11 at $249.12 ($71,248).
• Total: 572 shares sold for ~ $141,655.
• Footnotes: (F1) Trades executed under a pre‑approved 10b5‑1 plan, which is now completed; (F2) shares sold to cover taxes from RSUs granted June 6, 2025.
• Shares owned after transaction: Not disclosed in the provided filing.
• Filing: Form 4 filed 2026-06-11 (covers transactions on 6/10 and 6/11); filing appears timely.

Context Sales executed under a pre‑existing 10b5‑1 plan and those to cover tax withholding on RSU settlements are common and often routine. Such transactions do not necessarily indicate a change in the insider’s view of the company. For investors, purchases by insiders tend to be more informative about confidence than routine sales.